Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor
| Autor: | Roberto Soler, Ricarda M. Bauer, Frank Strittmatter, Christian Niedworok, Christian G. Stief, Karl-Erik Andersson, Peter Sandner, Christian Gratzke, Claudius Füllhase, Martin Hennenberg |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
medicine.diagnostic_test business.industry Urology media_common.quotation_subject Cystometry Endogeny Pharmacology medicine.disease Urination Nitric oxide chemistry.chemical_compound Endocrinology chemistry Vardenafil Internal medicine cGMP-specific phosphodiesterase type 5 Medicine Neurology (clinical) business Soluble guanylyl cyclase Urinary bladder disease medicine.drug media_common |
| Zdroj: | Neurourology and Urodynamics. 34:787-793 |
| ISSN: | 0733-2467 |
| DOI: | 10.1002/nau.22665 |
| Popis: | Aims To assess the urodynamic effects of soluble guanylyl cyclase (sGC) stimulator, BAY 41-2272, and activator, BAY 60-2770, (which both are able to induce cGMP synthesis even in the absence of nitric oxide (NO)) alone or in combination with a phosphodiesterase type 5 (PDE5) inhibitor, vardenafil, in a model of partial urethral obstruction (PUO) induced bladder overactivity (BO). Methods Fifty-six male Sprague–Dawley rats were used, 31 of them underwent PUO. Fourteen rats were used for Western blots to assess PDE5 and sGC expression. For drug evaluation cystometry without anesthesia was performed three days following bladder catheterization. Results Obstructed rats showed higher micturition frequency and bladder pressures than non-obstructed animals (Intermicturition Interval, IMI, 2.28 ± 0.55 vs. 3.60 ± 0.60 min (± standard deviation, SD); maximum micturition pressure, MMP, 70.1 ± 8.0 vs. 48.8 ± 7.2 cmH2O; both P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text